| 05/18 | Wells Fargo Adjusts MediWound's Price Target to $8 From $7, Keeps Overweight Rating | MT |
| 05/17 | SECTOR UPDATE : Health Care Stocks Rising Ahead of Tuesday Close | MT |
| 05/17 | SECTOR UPDATE : Health Care Stocks Firming with Broader Market Gains | MT |
| 05/17 | TRANSCRIPT : MediWound Ltd., Q1 2022 Earnings Call, May 17, 2022 | CI |
| 05/17 | MediWound Appoints Ofer Gonen as CEO | MT |
| 05/17 | MEDIWOUND : Q1 Earnings Snapshot | AQ |
| 05/17 | MediWound Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/17 | MediWound Announces CEO Transition | GL |
| 05/17 | MediWound Announces CEO Transition | GL |
| 05/17 | MediWound Reports First Quarter 2022 Financial Results | GL |
| 05/17 | Earnings Flash (MDWD) MEDIWOUND Reports Q1 Loss $-0.12, vs. Street Est of $-0.11 | MT |
| 05/17 | Earnings Flash (MDWD) MEDIWOUND Reports Q1 Revenue $4.4M, vs. Street Est of $4.29M | MT |
| 05/17 | MediWound Ltd. Announces Executive Changes | CI |
| 05/17 | Mediwound Ltd. Appoints Sharon Malka to the Company's Board of Directors | CI |
| 05/12 | MediWound Says Mid-Stage Trial of EscharEx for Debridement of Chronic Wounds Meet Prima.. | MT |
| 05/12 | MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debrid.. | GL |
| 05/12 | MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debrid.. | AQ |
| 05/12 | MediWound Ltd. Announces Positive Results from U.S. Phase 2 Clinical Study of Escharex®.. | CI |
| 05/12 | MediWound Shares Up After EscharEx Study Met Primary Endpoint | DJ |
| 05/10 | MediWound to Report First Quarter Financial Results and Host a Conference Call and Webc.. | GL |
| 05/10 | MediWound to Report First Quarter Financial Results and Host a Conference Call and Webc.. | GL |
| 04/13 | MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Ad.. | AQ |
| 04/12 | MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Ad.. | AQ |
| 03/30 | MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SA.. | AQ |
| 03/29 | MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SA.. | AQ |
| 03/22 | MEDIWOUND : Announces Exercise of Over-Allotment Option - Form 6-K | PU |
| 03/22 | MediWound Announces Exercise of Over-Allotment Option | GL |
| 03/21 | Aegis Capital Adjusts MediWound Price Target to $7 From $9, Maintains Buy Rating | MT |
| 03/21 | MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement.. | GL |
| 03/21 | MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement.. | CI |
| 03/17 | TRANSCRIPT : MediWound Ltd., Q4 2021 Earnings Call, Mar 17, 2022 | CI |
| 03/17 | MediWound Q4 Loss Widens, Revenue Declines | MT |
| 03/17 | MEDIWOUND : Q4 Earnings Snapshot | AQ |
| 03/17 | MEDIWOUND : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 6-K | PU |
| 03/17 | Earnings Flash (MDWD) MEDIWOUND Reports Q4 Revenue $5.5M, vs. Street Est of $5.54M | MT |
| 03/17 | MediWound Reports Fourth Quarter and Full Year 2021 Financial Results | GL |
| 03/17 | MediWound Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 | CI |
| 03/17 | MediWound Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021 | CI |
| 03/10 | MediWound Announces Closing of Public Offering of Ordinary Shares | AQ |
| 03/10 | MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Confe.. | AQ |
| 03/03 | MEDIWOUND : Announces Pricing of Public Offering of Ordinary Shares - Form 6-K | PU |
| 03/03 | MediWound Prices $10 Million Share Offering At Discount; Stock Falls | MT |
| 03/03 | MediWound Announces Pricing of Public Offering of Ordinary Shares | AQ |
| 03/02 | MEDIWOUND : Announces Proposed Public Offering of Ordinary Shares - Form 6-K | PU |
| 03/02 | MediWound Proposes Underwritten Public Offering of Ordinary Shares | MT |
| 03/02 | MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares | GL |
| 03/01 | MediWound to Present at Upcoming Investor Conferences in March | GL |
| 02/28 | MEDIWOUND : Presentation - January 2022 | PU |
| 02/17 | MediWound Awarded a U.S. Department of Defense Research Grant for the Development of Ne.. | GL |
| 02/17 | U.S. Department of Defense Awards Defense Research Grant to Mediwound Ltd. for the Deve.. | CI |
| 02/14 | MediWound to Present at Upcoming Investor Conferences in February | GL |
| 02/14 | MediWound to Present at Upcoming Investor Conferences in February | GL |
| 02/10 | MediWound Secures Additional $9 Million in BARDA Funding | MT |
| 02/10 | MEDIWOUND : Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA .. | PU |
| 02/10 | MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA.. | AQ |
| 02/10 | MediWound Ltd. announced that it has received $9 million in funding from Biomedical Adv.. | CI |
| 01/24 | Health Care Stocks Declining This Afternoon | MT |
| 01/24 | Health Care Stocks Dragged Lower in Broad-Based Equities Selloff | MT |
| 01/24 | Wall Street Set for Losses Amid Ukraine Crisis | MT |
| 01/24 | Health Care Stocks Retreat Premarket Monday | MT |
| 01/24 | Top Premarket Gainers | MT |
| 01/24 | MediWound Discloses 'Positive' Data From Phase 2 Study of Leg Ulcer Treatment | MT |
| 01/24 | MEDIWOUND : Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for.. | PU |
| 01/24 | MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx fo.. | GL |
| 01/24 | Mediwound Announces Positive Topline Results from Its U.S. Phase 2 Trial of Escharex fo.. | CI |
| 2021 | MediWound Says Phase 2 Study of EscharEx Treatment for Chronic Wounds Delivers Positive.. | MT |
| 2021 | MEDIWOUND : Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of Es.. | PU |
| 2021 | MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of E.. | AQ |
| 2021 | MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of E.. | CI |
| 2021 | MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study, Topl.. | AQ |
| 2021 | MediWound Completes Enrollment of Phase 2 Study of EscharEx; Shares Rise Pre-Bell | MT |
| 2021 | MEDIWOUND : Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study - Form.. | PU |
| 2021 | MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study | AQ |
| 2021 | MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study | CI |
| 2021 | EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid | GL |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
